This study is looking at how intermittent fasting, a daily eating plan with a 14-hour nightly fast and a 10-hour eating period, might affect women with HR+/HER2- (hormone receptor positive, HER2 negative) early breast cancer. Researchers want to see if participants can stick to this eating plan for six months and if it improves their quality of life while they are on adjuvant endocrine therapy (AET). The study will enroll 20 women who are at least 18 years old and have this specific type of breast cancer. Success for this study means participants can follow the fasting schedule.

Study design

This is a single-arm pilot study with 20 participants. It is designed to see if intermittent fasting is feasible and can lead to health improvements.

What's involved

Participants will be asked to follow a six-month intermittent fasting intervention, which involves a 14-hour nightly fast and a 10-hour eating period daily.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, adherence to the fasting schedule, is measured at six months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.